학술논문
Maraviroc Pharmacokinetics in HIV-1–Infected Pregnant Women
Document Type
article
Author
Colbers, Angela; Best, Brookie; Schalkwijk, Stein; Wang, Jiajia; Stek, Alice; Tenorio, Carmen Hidalgo; Hawkins, David; Taylor, Graham; Kreitchmann, Regis; Burchett, Sandra; Haberl, Annette; Kabeya, Kabamba; van Kasteren, Marjo; Smith, Elizabeth; Capparelli, Edmund; Burger, David; Mirochnick, Mark; van der Ende, ME; Erasmus, MC; van der Ven, AJAM; Nellen, J; Moltó, J; Nicastri, E; Giaquinto, C; Gingelmaier, A; Lyons, F; Lambert, J; Wyen, C; Faetkenheuer, G; Rockstroh, JK; Schwarze-Zander, C; Sadiq, S Tariq; Gilleece, Y; Wood, C; Buschur, Shelley; Jackson, Chivon; Paul, Mary; Florez, Claudia; Bryan, Patricia; Stone, Monica; Katz, Mindy; Auguste, Raphaelle; Wiznia, Andrew; Bruder, Karen L; Lewis, Gail; Casey, Denise; Losso, Marcelo H; Ivalo, Silvina A; Hakim, Alejandro; Deveikis, Audra; Batra, Jagmohan; Alvarez, Janielle Jackson; Knapp, Katherine M; Sublette, Nina; Wride, Thomas; Febo, Irma L; Santos, Ruth; Tamayo, Vivian
Source
Clinical Infectious Diseases. 61(10)
Subject
Language
Abstract
ObjectiveTo describe the pharmacokinetics of maraviroc in human immunodeficiency virus (HIV)-infected women during pregnancy and post partum.MethodsHIV-infected pregnant women receiving maraviroc as part of clinical care had intensive steady-state 12-hour pharmacokinetic profiles performed during the third trimester and ≥2 weeks after delivery. Cord blood samples and matching maternal blood samples were taken at delivery. The data were collected in 2 studies: P1026 (United States) and PANNA (Europe). Pharmacokinetic parameters were calculated.ResultsEighteen women were included in the analysis. Most women (12; 67%) received 150 mg of maraviroc twice daily with a protease inhibitor, 2 (11%) received 300 mg twice daily without a protease inhibitor, and 4 (22%) had an alternative regimen. The geometric mean ratios for third-trimester versus postpartum maraviroc were 0.72 (90% confidence interval, .60-.88) for the area under the curve over a dosing interval (AUCtau) and 0.70 (0.58-0.85) for the maximum maraviroc concentration. Only 1 patient showed a trough concentration (Ctrough) below the suggested target of 50 ng/mL, both during pregnancy and post partum. The median ratio of maraviroc cord blood to maternal blood was 0.33 (range, 0.03-0.56). The viral load close to delivery was